Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
Click here for original story, Targeted therapy proves effective against aggressive rare blood cancer
Source: ScienceDaily
Clinical study treating BPDCN with tagraxofusp led to first FDA approval for the disease.
Click here for original story, Targeted therapy proves effective against aggressive rare blood cancer
Source: ScienceDaily